Alkaline phosphatase for reducing systemic inflammatory response syndrome (SIRS) in patients with Sars-CoV-2 infection and acute respiratory insufficiency (COVID 19) - COVID-RESCAP

Rode Kruis Ziekenhuis0 个研究点目标入组 106 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•- Sars-CoV-2 infection based on: highly clinical suspicion on admission and/or
•positive PCR test on naso-pharynx swab or sputum and/or a CT imaging of the
•chest compatible with COVID-19 + type 1 or type 2 respiratory failure needing
•supplemental oxygen that indicates airway support or ICU admittance and meeting
•any of the following criteria: .
•- SpO2 <90% or PaO2/FiO2 < 200 mmHg
•- Clinical evidence of respiratory distress (RR > 25 breaths/minute)

•- Inclusion in another interventional clinical trial
•- Age < 18
•- Age > 80
•- Patients who are pregnant or lactating
•- Patients expected to have fatal disease within 24 hours
•- Patients who are already on dialysis (Renal Replacement Therapy, RRT) or a
•decision has been made to initiate RRT within 24 hours after planned start of
•study drug administration
•- Patients who have advanced chronic liver disease confirmed by a Child-Pugh C
•- Patients who are having a known history of immune system that has been
•impaired by disease, such as patients with HIV and with a CD4 count of less
•than 200 cells/mm, neutropenic patients (<0.5 x 109/l) Patients who are
•receiving chronic high doses (equivalent to prednisone/prednisolone 0.5
•mg/kg/day) steroids therapy immediately prior to recruitment exceeding 2 weeks
•of treatment. This means dexamethasone 6 mg once daily serving as treatment for
•severe COVID-19 is not an exclusion criterion.
•- Patients with active haematological malignancy

发起方

Rode Kruis Ziekenhuis